101
|
Chiodini PG, Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine. J Clin Endocrinol Metab 1985; 60:48-52. [PMID: 3917270 DOI: 10.1210/jcem-60-1-48] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
We studied the effects of 100 micrograms human pancreatic GH releasing hormone-44 (GRH) in 35 acromegalic patients. Plasma GH levels significantly increased [basal, 30 +/- 10 (SE) ng/ml; peak, 82 +/- 21 ng/ml; P less than 0.01], but a wide intersubject variability of the responses was found (range, 20-1602%). No relationship was found between the percentage GH increase after GRH and basal values of GH, PRL, or somatomedin-C. All patients also underwent an acute test with bromocriptine (2.5 mg orally) and TRH (200 micrograms iv). When dividing the patients according to their GH responsiveness to bromocriptine (Br), an inverse correlation (r = -0.42, P less than 0.05) was found between percentage of GH changes after GRH and after Br; moreover Br responder patients had a lesser (P less than 0.001) GH increase after GRH (124 +/- 27%) than nonresponders (562 +/- 116%). No relationship was found between the GH response to TRH and GRH, and no differences were found between the percentage GH increase after TRH (513 +/- 117%) and after GRH (349 +/- 71%). We conclude that the tumoral somatotrophs are sensitive to their specific releasing hormone and we suggest that the presence in the adenoma of cells with surface membrane receptors similar to those on the lactotropes may explain the lower sensitivity to GRH of Br responders compared to nonresponders.
Collapse
|
102
|
Oppizzi G, Liuzzi A, Chiodini P, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Tonon C. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. J Clin Endocrinol Metab 1984; 58:988-92. [PMID: 6725515 DOI: 10.1210/jcem-58-6-988] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
We studied the effects of long term treatment with bromocriptine (Br) or lisuride (L) on GH secretion and tumor size in 19 acromegalic patients with large pituitary adenomas. In 22 additional patients with smaller adenomas, only plasma GH levels were monitored during treatment. All patients underwent an acute test with 2.5 mg Br or 0.3 mg L and, on the basis of GH changes, were classified as responders, i.e. reduction in circulating GH concentrations by at least 50% below baseline, or as nonresponders. The chronic treatment was 5-20 mg/day Br in 26 patients or 0.3-2.0 mg/day L in 15 patients. Treatment was given for 4-26 months (mean +/- SE, 13.3 +/- 2.8 months). Plasma GH levels (baseline, 46.3 +/- 8.3 ng/ml) were significantly lower in the group as a whole (22.7 +/- 3.6 ng/ml; P less than 0.01) after the first month of treatment with dopamine agonist agents. GH levels decreased significantly in those acromegalic patients who responded to the acute test (P less than 0.001), but were unchanged in the nonresponders. In addition, there was a significant correlation between the maximal percent GH decrease in the acute test and the response during chronic treatment (r = 0.73; P less than 0.01). Computed tomography failed to show any tumor size changes in any of the GH nonresponders who had a macroadenoma . However, in two patients in the acute responder group with macroadenomas, chronic dopamine agonist therapy resulted in reduction of the extrasellar portion of the tumor (-30% and -40% of tumor area, respectively). These data show that although dopaminergic drugs lower GH levels and reverse signs and symptoms of active disease in those acromegalic patients who are responsive to an acute challenge, tumor size reduction occurred in a minority of such patients.
Collapse
|
103
|
Verde G, Loli P, Berselli ME, Tagliaferri M, Dallabonzana D, Oppizzi G, Liuzzi A, Chiodini PG, Luccarelli G, Lodrini S. Cushing's disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment. J Endocrinol Invest 1984; 7:51-4. [PMID: 6715796 DOI: 10.1007/bf03348376] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The case of a young boy bearing a pituitary PRL secreting adenoma (20-30,000 ng/ml) with the unusual association of clinical and endocrinological features of Cushing's disease successfully treated with bromocriptine is described. Brain computed tomography evidenced a huge pituitary adenoma leading to visual field defects and raised intracranial pressure. Due to the very large size of the tumor, which rendered the complete neurosurgical removal unlikely, medical treatment with bromocriptine (10 mg/day) was started. Follow-up for more than six months demonstrated an impressive reduction of tumor size, the lowering of prolactin levels into the normal range, the normalization of visual field, and the regression of both clinical and biochemical signs of hypercortisolism.
Collapse
|
104
|
Lamberts SW, Klijn JG, van Vroonhoven CC, Stefanko SZ, Liuzzi A. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. ACTA ENDOCRINOLOGICA 1983; 103:446-50. [PMID: 6310918 DOI: 10.1530/acta.0.1030446] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
UNLABELLED Bromocriptine treatment results in clinical improvement and inhibition of plasma GH levels in only part of the acromegalic patients. The possible role of the simultaneous presence of Prl and GH in GH-secreting pituitary adenomas was investigated with regard to the inhibitory action of bromocriptine on GH secretion and the paradoxical increase of GH release in reaction to TRH. Surgically obtained pituitary tumour tissue from 35 consecutive acromegalic patients was studied immunohistochemically. In 21 patients no Prl was present in the tumour tissue. These patients had normal plasma Prl levels. In the other 14 patients Prl was present in the tumour tissue. Hyperprolactinaemia was found in 10 of these 14 patient. Plasma GH levels from 2 till 10 h after the administration of 2.5 mg bromocriptine measured before operation were significantly more suppressed in the patients with mixed GH/Prl-containing than in those with pure GH-containing pituitary adenomas, being 38 +/- 4% and 65 +/- 4% of basal values, respectively (P less than 0.01). The response of GH to TRH, however, did not differ significantly between the two groups. CONCLUSIONS 1. In about 70% of patients with 'mixed' GH/Prl containing adenomas, hyperprolactinaemia is present. 2. The simultaneous presence of Prl and GH in a GH-secreting pituitary tumour increases the sensitivity of GH secretion to bromocriptine. 3. The plasma Prl level is of value to predict which patients with acromegaly are likely to respond to bromocriptine with an inhibition of GH secretion.
Collapse
|
105
|
Dallabonzana D, Spelta B, Oppizzi G, Tonon C, Luccarelli G, Chiodini PG, Liuzzi A. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J Endocrinol Invest 1983; 6:47-50. [PMID: 6841916 DOI: 10.1007/bf03350560] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
We report two cases with macroprolactinoma who during medical treatment with bromocriptine showed a normalization of PRL levels and a reduction of tumor size as documented by computed tomography. After a few months of therapy both patients suddenly complained of worsening of their visual fields and a computed tomography demonstrated a reenlargement of the tumor mass; whereas in one patient PRL levels remained always within normal range, in the other patient, who was taking spiramycin for an intercurrent illness, there was also an escape of the hormonal secretion from the inhibitory effect of bromocriptine. The first patient underwent surgery, whereas in the second patient continuation of bromocriptine and interruption of antibiotic treatment resulted in progressive improvement in visual fields and a reduction of tumor size again. We want to stress that in patients with macroprolactinomas responsive to the medical treatment both in terms of PRL secretion and of tumor size reduction, an escape from the effects of bromocriptine, although infrequently, may occur.
Collapse
|
106
|
Dallabonzana D, Spelta B, Botalla L, Oppizzi G, Silvestrini F, Chiodini PG, Liuzzi A. Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia. J Clin Endocrinol Metab 1982; 54:1125-8. [PMID: 7076795 DOI: 10.1210/jcem-54-6-1125] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
We have studied the effect of the oral administration of 200 mg nomifensine (nom), a drug which activates the dopaminergic system, on GH and PRL secretion in 15 normal subjects, 18 patients with idiopathic hyperprolactinemia, and 17 patients with tumoral hyperprolactinemia. GH levels increased significantly after nom in normal subjects (basal, 0.96 +/- 0.76 ng/ml; peak 4.6 +/- 0.61 ng/ml; P less than 0.01) and patients with hyperprolactinemia, both idiopathic (basal, 1.0 +/- 0.38 ng/ml; peak, 4.2 +/- 1.0 ng/ml; P less than 0.05) and tumoral (basal 0.88 +/- 0.3 ng/ml, peak 6.68 +/- 1.2 ng/ml; P less than 0.01). Peak GH levels higher than 5 ng/ml were observed in 8 of 15 normal subjects, 6 of 18 patients with idiopathic hyperprolactinemia, and 8 of 17 patients with tumoral hyperprolactinemia. PRL levels decreased in response to nom in normal subjects, but not in patients with idiopathic or tumoral hyperprolactinemia. A reduction in plasma PRL levels of at least 30% below the baseline was observed only in two patients with idiopathic hyperprolactinemia and in none of the patients with tumoral hyperprolactinemia. These results demonstrate that nom does not discriminate between idiopathic and tumoral hyperprolactinemia. Since nom probably requires a hypothalamic pool of dopamine to bring about its GH stimulatory effect, the suggestion that the lack of a PRL-lowering effect of the drug is attributable to a dopamine deficiency is not supported by our data.
Collapse
|
107
|
Lamberts SW, Liuzzi A, Chiodini PG, Verde S, Klijn JG, Birkenhäger JC. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 1982; 12:151-5. [PMID: 6807686 DOI: 10.1111/j.1365-2362.1982.tb00952.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
UNLABELLED The mechanism of the inhibition of growth hormone secretion in response to bromocriptine and the ability of thyrotropin releasing hormone to stimulate growth secretion in acromegaly is unknown. In the present study the relationship between the plasma prolactin concentration of untreated acromegalic patients and the reaction of growth hormone to thyrotropin releasing hormone and bromocriptine was investigated. Plasma prolactin levels were elevated in thirty-three (42%) of seventy-nine untreated acromegalic patients. Seventeen patients had mildly elevated prolactin levels, but in sixteen the plasma prolactin concentration was higher than 30 ng/ml. Bromocriptine (2.5 mg) inhibited growth hormone secretion by more than 50% in 22% of the normoprolactinaemic, in 53% of the mild hyperprolactinaemic and in 88% of the patients with a prolactin level above 30 ng/ml (P less than 0.01 v. normoprolactinaemic; P less than 0.01 v. mildly elevated prolactin levels). An increase of growth hormone secretion by more than 100% of the basal value in response to thyrotropin releasing hormone was observed in 44% of the normoprolactinaemic, in 59% of the mildly hyperprolactinaemic and in 75% of the clearly hyperprolactinaemic patients; (P less than 0.01 v. normo- and mildly hyperprolactinaemic patients). CONCLUSION An increased plasma prolactin concentration in patients with acromegaly is accompanied in most patients by a higher sensitivity of growth hormone secretion to bromocriptine.
Collapse
|
108
|
Crosignani PG, Ferrari C, Liuzzi A, Benco R, Mattei A, Rampini P, Dellabonzana D, Scarduelli C, Spelta B. Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride. Fertil Steril 1982; 37:61-7. [PMID: 7199483 DOI: 10.1016/s0015-0282(16)45978-9] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
One hundred ninety-one hyperprolactinemic patients (78 women and 13 men; 54 with pituitary macroadenoma, 53 with microadenoma, and 84 with idiopathic disease) were treated for 2 to 48 months with one or two of the following prolactin (PRL)-lowering drugs: bromocriptine, metergoline, and lisuride. All of the three drugs used were highly effective in lowering PRL levels and restoring gonadal function both in females and in males in the majority of patients with either idiopathic or tumorous disease. In poorly responsive patients, increasing the drug doses resulted in further PRL lowering for all the three drugs. Mild side effects were frequently encountered with initiation of drug treatment but spontaneously subsided in most cases; severe side effects, necessitating stopping of the treatment, occurred in only 12 instances, but changing of the drug allowed PRL-lowering treatment to be continued in 11 of them.
Collapse
|
109
|
|
110
|
Chiodini P, Liuzzi A, Cozzi R, Verde G, Oppizzi G, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Luccarelli G, Rainer E, Horowski R. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab 1981; 53:737-43. [PMID: 7287863 DOI: 10.1210/jcem-53-4-737] [Citation(s) in RCA: 101] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
We have administered to 29 patients with macroprolactinoma the dopamine agonists bromocriptine and lisuride for 1-50 months (mean +/- SE, 12.7 +/- 1.8) in order to assess the effects of these drugs on tumor size. Fourteen patients were treated with bromocriptine (dose range, 7.5-20 mg/day), 12 patients were treated with lisuride (0.6-2 mg/day), and 3 patients were given both drugs. Computed tomography performed before and during treatment showed the occurrence of tumor shrinkage in 18 patients (62%), but in no case was a complete disappearance of the tumor observed. In 5 of these patients, it was even possible to document tumor shrinkage within the first month of treatment with low doses of the dopamine agonists, whereas in other patients, tumors shrank only after prolonged treatment with higher doses. Visual field and acuity improved or normalized in 8 of the 13 patients with visual defects; in some cases, the improvement was reported as early as 2 days after the treatment was started. Plasma PRL levels fell in all patients who showed a reduction in tumor size; in 2 other patients, PRL levels were only poorly suppressed, and tumor size remained unchanged. In the remaining patients, PRL levels were lowered without convincing evidence of tumor shrinkage. In considering the high percentage of patients showing tumor shrinkage under medical treatment, we propose a course with dopamine agonists as the first step in the management of patients with macroprolactinomas regardless of the presence of visual impairments.
Collapse
|
111
|
Verde G, Chiodini PG, Liuzzi A, Cozzi R, Favales F, Botalla L, Spelta B, Dalla Bonzana D, Rainer E, Horowski R. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. J Endocrinol Invest 1980; 3:405-14. [PMID: 6782153 DOI: 10.1007/bf03349379] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
We have studied the effects of the chronic administration of the dopamine agonist lisuride (L) in 21 acromegalics (group 1) and in 25 patients with pathological hyperprolactinemia (group 2). Before starting the treatment levels of PRL and/or GH were determined during acute tests with L (0.3 mg po) or TRH (0.2 mg iv). L was given in doses ranging between 0.4 and 2.4 mg/day. GH and/or PRL were determined at monthly intervals, TRH (6 patients of group 1 and 10 of group 2) was repeated during L therapy. In 10 patients of group 1 GH levels were reduced below 10 ng/ml by L therapy; in the remaining patients GH levels were reduced by 50% of the pretreatment values or they were unchanged. The correlation (p less than 0.01) found between GH levels during acute and chronic L administration indicates that GH changes after acute test are predictive of the outcome of the treatment. In all patients PRL was reduced during the therapy to at least 50% of the basal values and in most patients PRL fell to the normal range. No correlation was found between PRL levels during acute and chronic L administration. During the therapy TRH still increased GH levels in most patients whereas it failed to raise PRL. The withdrawal of L was followed by a rapid return of GH to the pretreatment values whereas PRL showed a slower increase. In acromegalics whose GH was lowered by L there was also a marked amelioration of clinical and metabolic parameters. The lowering of PRL was accompanied by the resumption of ovulatory menses even in patients with tumoral hyperprolactinemia. Males reported improvement in sexual performance. An improvement of visual field occurred in 1 patient. In 1 patient with a large prolactinoma serial computerized tomography scans performed during 2 yr of treatment showed a marked reduction of the tumor size.
Collapse
|
112
|
Oppizzi G, Botalla L, Verde G, Cozzi R, Liuzzi A, Chiodini PG. Homogeneity in the growth hormone-lowering effect of dopamine and somatostatin in acromegaly. J Clin Endocrinol Metab 1980; 51:616-9. [PMID: 6106023 DOI: 10.1210/jcem-51-3-616] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
We have studied the effect of maximally inhibiting doses of dopamine (DA) or somatostatin on GH levels in 39 acromegalic patients. The GH-lowering effects of the two drugs were highly variable in different patients. A significant correlation (r = 0.45; P < 0.01) was found between the percent changes obtained during the infusions of DA (500 microgram/min) and somatostatin (3.33 microgram/min). Pretreatment with L-sulpiride markedly blunted the inhibitory effect of DA but did not affect the response to somatostatin. We conclude that the GH-secreting cells of acromegalic patients contain separate receptors for DA and somatostatin. We hypothesize that the partial or total lack of responsiveness to DA or somatostatin may be due to the loss of receptors for these agents on the GH-secreting neoplastic cells.
Collapse
|
113
|
Silvestrini GF, Gelli D, Liuzzi A, Chiodini PG, Cozzi R, Loli R, Verde G, Beretta A, Bonomo M, Bosisio C, Colombo G, Cremoncini M, De Risi A, Favales F, Frascatani F, Goi D, Maggioni D, Mauri R, Muratori F, Perrino L, Ravanelli M, Riolo A, Ronzoni M, Spelta B, Valente C. Neuroactive drugs in endocrine diseases: notes on their physiopathological and therapeutical aspects. Panminerva Med 1980; 22:61-71. [PMID: 6111063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
114
|
Chiodini PG, Liuzzi A, Verde G, Cozzi R, Silvestrini F, Marsili MT, Horowski R, Passerini F, Luccarelli G, Borghi PG. Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride. Clin Endocrinol (Oxf) 1980; 12:47-51. [PMID: 7379313 DOI: 10.1111/j.1365-2265.1980.tb03131.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
A 38-year-old amenorrhoeic woman suffering from a prolactin (PRL) secreting adenoma, which had suprasellar extension as shown by caroe agonist (lisuride). PRL levels were lowered and after 1 year of treatment CAT showed a marked reduction of the tumour size. After 2 years of treatment menstruation returned and CAT demonstrated a further reduction of the adenomatous tissue. This study supports the suggestion that dopamine agonists possess an anti-proliferative effect on tumoural lactotrophic cells of humans.
Collapse
|
115
|
Verde G, Chiodini PG, Liuzzi A, Favales F, Cozzi R. Bromocriptine and pituitary tumours. Lancet 1979; 2:582. [PMID: 89580 DOI: 10.1016/s0140-6736(79)91635-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
116
|
Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano L, Colussi G, Gräf KJ, Horowski R. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans. J Clin Endocrinol Metab 1978; 46:196-202. [PMID: 108287 DOI: 10.1210/jcem-46-2-196] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
In 12 acromegalics a single oral dose of 0.2 mg lisuride, an ergoline derivative, significantly reduced plasma PRL but not GH concentrations. Three-tenths milligram of the drug significantly reduced plasma levels of the two hormones. Four-tenths milligram of lisuride did not augment this inhibitory effect. Plasma PRL levels were suppressed in all patients, whereas GH levels were reduced by more than 50% of the base-line values in only seven patients who also responded to the administration of 2.5 mg bromocriptine (CB154). In the patients unresponsive to lisuride, CB154 also failed to change GH levels. The suppressive effect of lisuride started at 60 min (at 150 min for CB154) and plasma GH and PRL levels were still markedly suppressed at 300 min. Plasma GH and PRL concentrations were consistently reduced in two acromegalic patients during 2 weeks of chronic treatment with 0.3 mg lisuride four times a day. In six normal subjects, TRH-induced PRL release was significantly inhibited by pretreatment with 0.3 mg of the drug. The similarity in the effects of lisuride and CB154 suggests that the observed effects of lisuride on GH and PRL are attributable to the known dopaminergic activity of the drug. This conclusion is supported by the data showing that pimozide effectively counteracted the inhibitory action of lisuride on GH and PRL release. We suggest that lisuride may be of value in the medical treatment of acromegaly and hyperprolactinemic states.
Collapse
|
117
|
Silvestrini F, Liuzzi A, Chiodini PG. Prolactin and pituitary tumors. CURRENT TOPICS IN EXPERIMENTAL ENDOCRINOLOGY 1978; 3:131-72. [PMID: 26521 DOI: 10.1016/b978-0-12-153203-1.50011-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
118
|
Silvestrini F, Liuzzi A, Chiodini PG. Effect of ergot alkaloids on growth hormone and prolactin secretion in humans. Pharmacology 1978; 16 Suppl 1:78-87. [PMID: 643905 DOI: 10.1159/000136810] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The effects of ergot alkaloids (mainly bromocriptine) on the secretion of GH and PRL in normal subjects and in pathological conditions (i.e. acromegaly and hyperprolactinemic states) are discussed. In the normal subjects, bromocriptine releases GH whereas in about 50% of acromegalics it causes a marked and long-lasting inhibition of the hormone secretion. PRL release is reduced by the drug both in normal subjects and in hyperprolactinemic states. Physiopathological studies in the humans indicate that, according to the experimental data, bromocriptine inhibits GH release in acromegaly and PRL secretion through a dopaminergic mechanism of action playing at the pituitary level. Data are reported on the effectiveness of bromocriptine in the medical treatment of acromegaly and of hyperprolactinemic states.
Collapse
|
119
|
Liuzzi A, Foppen FH, Kopin IJ. Stimulation and maintenance by nerve growth factor of phenylethanolamine-N-methyltransferase in superior cervical ganglia of adult rats. Brain Res 1977; 138:309-15. [PMID: 589478 DOI: 10.1016/0006-8993(77)90748-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Treatment of newborn rats with nerve growth factor (NGF) results in a striking increase in phenylethanolamine-N-methyltransferase (PNMT) in the superior cervical ganglia. Between one and three weeks of age there is normally a 10-fold decrease in PNMT activity in ganglia of infant rats. NGF treatment maintains the PNMT in ganglia at levels 10-fold greater than in untreated controls, but the levels of enzyme in the ganglion show the same magnitude of decrease with age. Epinephrine levels are markedly increased in ganglia of NGF-treated rats younger than one week of age, but at older ages the levels of the catecholamine are only slightly greater than the controls. Dexamethasone is less effective than NGF in increasing the levels of PNMT in ganglia of infant rats and, unlike NGF, becomes ineffective by 44 days of age. These results suggest that there may be two types of PNMT-containing cells in ganglia of newborn rats.
Collapse
|
120
|
Oppizzi G, Verde G, De Stefano L, Cozzi R, Botalla L, Liuzzi A, Chiodini PG. Evidence for a dopaminergic activity of methysergide in humans. Clin Endocrinol (Oxf) 1977; 7:267-72. [PMID: 923106 DOI: 10.1111/j.1365-2265.1977.tb01325.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The acute administration of 2 mg of methysergide significantly reduced plasma prolactin levels in nine normal subjects and in seven hyperprolactinaemic patients. The prolactin lowering effect of this drug was abolished by sulpiride. Morever methysergide lowered plasma GH levels in four out of nine acromegalic patients, who were also responsive to a dopaminergic drug such as bromocriptine. Although methysergide did not significantly blunt the TRH-induced prolactin release, our data suggest that this drug may affect GH and prolactin release through a dopaminergic mechanism of action. This effect should be taken into account when methysergide is employed as antiserotoninergic drug in neuroendocrinological studies.
Collapse
|
121
|
Liuzzi A, Foppen FH, Saavedra JM, Levi-Montalcini R, Kopin IJ. Gas chromatographic-mass spectrometric assay of serotonin in rat superior cervical ganglia. Effects of nerve growth factor and 6-hydroxydopamine. Brain Res 1977; 133:354-7. [PMID: 902099 DOI: 10.1016/0006-8993(77)90771-5] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
122
|
Liuzzi A, Foppen FH, Saavedra JM, Jacobowitz D, Kopin IJ. Effect of NGF and dexamethasone on phenyl-ethanolamine-N-methyl transferase (PNMT) activity in neonatal rat superior cervical ganglia. J Neurochem 1977; 28:1215-20. [PMID: 874482 DOI: 10.1111/j.1471-4159.1977.tb12312.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
123
|
Belforte L, Camanni F, Chiodini PG, Liuzzi A, Massara F, Molinatti GM, Müller EE, Silvestrini F. Long-term treatment with 2-Br-alpha-ergocryptine in acromegaly. ACTA ENDOCRINOLOGICA 1977; 85:235-48. [PMID: 405832 DOI: 10.1530/acta.0.0850235] [Citation(s) in RCA: 42] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Thirty acromegalic subjects underwent chronic CB154 therapy (10-20 mg daily) for periods ranging from 3 months up to 2 years. In 18 out of 21 patients, who exhibited consistent HGH reduction following acute administration of the drug, there was also during chronic treatment, a suppression of the plasma HGH levels exceeding 50% of base line values, e.g. from mean daily values between 14-197 ng/ml (mean +/- SEM = 57.8 +/- 12.4 ng/ml pre-treatment) to 2-19 ng/ml (mean 8.3 +/- 1.2 ng/ml post-treatment). In 12 of the subjects who responsed to chronic CB154 treatment, the mean daily values of HGH were below 10 ng/ml. The suppression of plasma HGH was maintained unaltered throughout the whole course of therapy. In the 9 subjects, in whom no consistent HGH decrease was evidenced with acute CB154 administration, there was accordingly a minor or no suppression of HGH values during the chronic treatment. In 13 subjects, irrespective of the degree of their GH responses, the plasma prolactin levels were constantly inhibited by CB154; instead the drug failed to modify significantly the TRH or insulin-induced GH release. These changes in the hormonal parameters were paralleled by marked clinical amelioration and improvement of some of the metabolic alterations frequently encountered in acromegaly, e.g. reduced carbohydrate tolerance, increased insulin resistance, diminished fall of plasma phosphorus after insulin, decreased urinary excretion of phosphate, hyper-hydroxyprolinuria and hyper-calciuria. Collectively, these data demonstrate that CB154 thrapy is effective in reducing HGH hyper-secretion in many acromegalic patients during long-term treatment.
Collapse
|
124
|
Foppen FH, Liuzzi A, Kopin IJ. Gas chromatographic-mass spectrometric identification of epinine in rat superior cervical ganglia and formation in vivo. EXPERIENTIA 1977; 33:596-8. [PMID: 862780 DOI: 10.1007/bf01946518] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Epinine was identified in rat superior cervical ganglia by a gas chromatographic-mass spectrometric method. The deuterated methyl group of i.v. administered labeled methionine was incorporated into epinine at a slow rate, although epinephrine-CD3 was rapidly formed. These results indicate that epinine found in the ganglia is not a precursor of epinephrine.
Collapse
|
125
|
Wass JA, Thorner MO, Besser GM, Morris D, Mason AS, Liuzzi A, Chiodini PG. Gastrointestinal bleeding in patients on bromocriptine. Lancet 1976; 2:851. [PMID: 61520 DOI: 10.1016/s0140-6736(76)91233-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
126
|
Chiodini PG, Liuzzi A, Muller EE, Botalla L, Cremascoli G, Oppizzi G, Verde G, Silvestrini F. Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients. J Clin Endocrinol Metab 1976; 43:356-63. [PMID: 950367 DOI: 10.1210/jcem-43-2-356] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Plasma levels of growth hormone (GH) and prolactin (PRL) were measured in twelve acromegalic patients after acute administration of an ergoline derivative (methergoline) which has been proposed as a specific serotoninergic blocking agent. The administration of methergoline (4 mg p.o.) was followed by a significant decrease in plasma GH and PRL concentrations. The administration to the same subjects of CB 154 (2.5 mg p.o.), a known stimulator of dopaminergic receptors, led to results almost superimposable to those obtained with methergoline although the suppressive effect of CB 154 on GH and PRL levels was more sustained. Also on the ground of results obtained in these patients with the use of cyproheptadine, phentolamine, or pimozide, we have concluded that methergoline inhibition of GH and PRL release is, in acromegalic patients, most probably due to a dopaminergic mechanism of action.
Collapse
|
127
|
Verde G, Oppizzi G, Colussi G, Cremascoli G, Botalla L, Müller EE, Silvestrini F, Chiodini PG, Liuzzi A. Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in agromegalic patients. Clin Endocrinol (Oxf) 1976; 5:419-23. [PMID: 971548 DOI: 10.1111/j.1365-2265.1976.tb01971.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
In ten normal subjects and in twenty acromegalic patients plasma levels of growth hormone were studied after administration of L-dopa and a dopamine infusion. In the ten normal subjects L-dopa, but not dopamine, increased plasma levels of GH. In the acromegalic patients both L-dopa and dopamine were followed by an inhibition of GH release. Since dopamine does not cross the blood-brain barrier, these results, although not excluding a site of action at median eminence level, support the thesis that the inhibitory effect of dopaminergic stimulation on GH release in acromegaly possibly involves receptors present on GH-secreting cells.
Collapse
|
128
|
Udeschini G, Cocchi D, Panerai AE, Gil-Ad I, Rossi GL, Chiodin PG, Liuzzi A, Müller EE. Stimulation of growth hormone release by thyrotropin-releasing hormone in the hypophysectomized rat bearing an ectopic pituitary. Endocrinology 1976; 98:807-14. [PMID: 816640 DOI: 10.1210/endo-98-3-807] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Hypophysectomized female rats which received renal grafts of anterior pituitary (AP) or weight-matched intact controls were sampled under urethane anesthesia. Plasma growth hormone (GH) in sequential samples from each rat was measured by radioimmunoassay to determine the effect of exogenous thyrotropin-releasing hormone (TRH) on GH release from ectopic or intact AP. In a first experiment, following a baseline sample, a pre-treatment sample was taken from each rat 30 min after urethane injection, after which TRH (0.3 or 0.6 mug) or isotonic saline was injected iv, and samples were taken at 10 and 30 min post-treatment. Baseline GH levels in hypophysectomized-transplanted rats were in the range of 4.0 to 8.0 ng/ml, and were not modified significantly by urethane. TRH caused a significantly greater increase in growth hormone at 10 min than did saline. Plasma GH tended to be higher at 30 min post-treatment only in the 0.6 mug TRH-treated group. In further experiments the above described protocol was followed except that four doses of TRH were used (0.15, 0.3, 0.6, and 1.2 mug) and post-TRH blood samples were taken at 5 and 10 min. TRH caused a clear-cut increase in plasma GH both at 5 and 10 min, although no dose-effect relationship was present. In intact controls, baseline GH levels were in the range 40.0 to 80.0 ng/ml and were drastically reduced by urethane. In these animals, only the 1.2 mug TRH dose induced a GH rise at 5 and 10 min. In similar experiments, iv administration of vasopressin (100, 200, or 400 mU) induced a rise in plasma GH when given to the hypohysectomized-transplanted rats, but was ineffective in intact controls; the administration of prostaglandin E2 (5.0 and 50.0 mug) increased plasma GH in both experimental conditions. The results indicate that TRH in the hypophysectomized-transplanted rat acts directly on the AP tissue to increase GH release and that the ectopic pituitary is more susceptible than the in situ pituitary to some GH-releasing stimuli.
Collapse
|
129
|
Chiodini PG, Liuzzi A, Botalla L, Oppizzi G, Müller EE, Silvestrini F. Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergocryptine (CB-154) in acromegalic patients. J Clin Endocrinol Metab 1975; 40:705-8. [PMID: 1127079 DOI: 10.1210/jcem-40-4-705] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
In 7 acromegalic patients in whom plasma hGH concentrations had dropped acutely after a single dose of 2-B r-alpha-ergocryptine (CB-154, 2.5 mg orally) chronic CB-154 treatment (10 mg orally for 30 days) was also accompanied by a significant and stable reduction of hGH. Withdrawal of the drug was followed by a rapid return of hGH to pretreatment values. Reinstatement of oral CB-154 treatment resulted again in suppression of hGH levels measured 30 and 60 days later. In 5 patients, unresponsive to acute administration of CB-154, no appreciable variation in hGH levels was present after 30 days of treatment. These results suggest that 2-Br-alpha-ergocryptine offers a new approach to the medical treatment of acromegaly.
Collapse
|
130
|
Müller EE, Liuzzi A, Chiodini PG, Silvestrini F. Letter: Treatment of acromegaly. Lancet 1975; 1:468. [PMID: 48669 DOI: 10.1016/s0140-6736(75)91550-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
131
|
Liuzzi A, Chiodini PG, Botalla L, Silvestrini F, Müller EE. Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses. J Clin Endocrinol Metab 1974; 39:871-6. [PMID: 4214404 DOI: 10.1210/jcem-39-5-871] [Citation(s) in RCA: 81] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
132
|
Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Müller EE, Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration. J Clin Endocrinol Metab 1974; 38:910-2. [PMID: 4823928 DOI: 10.1210/jcem-38-5-910] [Citation(s) in RCA: 136] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
133
|
Liuzzi A, Foppen FH, Angeletti PU. Adrenaline, noradrenaline and dopamine levels in brain and heart after administration of 6-hydroxydopamine and guanethedine to newborn mice. Biochem Pharmacol 1974; 23:1041-4. [PMID: 4824904 DOI: 10.1016/0006-2952(74)90003-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
134
|
Liuzzi A, Chervenak J. A comparison of measured primary X-ray spectra from molybdenum and tungsten targets due to bombardment by monoenergetic electrons in the energy range 10 to 30 keV. Phys Med Biol 1974. [DOI: 10.1088/0031-9155/19/2/116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
135
|
Chiodini PG, Liuzzi A, Botalla L, Cremascoli G, Silvestrini F. Inhibitory effect of dopaminergic stimulation on GH release in acromegaly. J Clin Endocrinol Metab 1974; 38:200-6. [PMID: 4812616 DOI: 10.1210/jcem-38-2-200] [Citation(s) in RCA: 71] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
136
|
Chiodini PG, Liuzzi A, Cremascoli G, Botalla L. [Changes of somatotropinemia in patients with acromegaly following administration of L-dopa]. FOLIA ENDOCRINOLOGICA 1973; 26:497-502. [PMID: 4801260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
137
|
Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Tosi M. [Studies of hypothalamic control of somatotropin incretion in acromegaly]. FOLIA ENDOCRINOLOGICA 1973; 26:503-9. [PMID: 4801261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
138
|
Vignati E, Liuzzi A, Chiodini PG. [Treatment of diabetes mellitus with glibornurid]. Minerva Med 1973; 64:3900-6. [PMID: 4767761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
139
|
Silvestrini F, Liuzzi A, Chiodini PG, Cattabeni A, Botalla L. [Behavior of plasmatic TSH in pituitary neoplasms after stimulation with thyrotropin releasing hormone (TRH)]. FOLIA ENDOCRINOLOGICA 1973; 26:398-406. [PMID: 4203133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
140
|
Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Silvestrini F. Inhibitory effect of L-Dopa on GH release in acromegalic patients. J Clin Endocrinol Metab 1972; 35:941-3. [PMID: 4634493 DOI: 10.1210/jcem-35-6-941] [Citation(s) in RCA: 94] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
141
|
Liuzzi A, Chiodini PG, Botalla L, Cattabeni A, Tosi M, Cremascoli G. [Secretion dynamics of GH in 43 patients with acromegaly]. FOLIA ENDOCRINOLOGICA 1972; 25:393-400. [PMID: 4679241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
142
|
Liuzzi A, Keaney J, Freedman G. Use of activated charcoal for the collection and containment of 133 Xe exhaled during pulmonary studies. J Nucl Med 1972; 13:673-6. [PMID: 5054858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
143
|
Liuzzi A, Chiodini PG, Botalla L, Silvestrini F. [Role of medroxyprogesterone acetate (MPA) on the blood level of STH in 12 patients with acromegaly]. ANNALES D'ENDOCRINOLOGIE 1972; 33:426-30. [PMID: 4664003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
144
|
Chiodini PG, Liuzzi A, Spinelli F, Botalla L, Silvestrini F. [STH blood level after metopirone in 12 patients with acromegaly]. ANNALES D'ENDOCRINOLOGIE 1972; 33:431-5. [PMID: 4664004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
145
|
Chiodini PG, Liuzzi A, Spinelli-Ressi F, Botalla L, Silvestrini F. [Effects of pharmacological or surgical correction of hypercortisolism on incretion of S.T.H. in Cushing's syndrome]. FOLIA ENDOCRINOLOGICA 1972; 25:230-8. [PMID: 4677771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
146
|
Cremoncini C, Liuzzi A. [Tybamate, recently synthetized anxiolytic agent, in the treatment of emotional and neurovegetative symptoms of hyperthyroidism. Clinico-statistical study]. Minerva Med 1972; 63:296-307. [PMID: 5012345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
147
|
Silvestrini F, Liuzzi A, Chiodini PG. [Behavior of blood somatotropin in states of hyperadrenocorticism]. FOLIA ENDOCRINOLOGICA 1971; 24:369-76. [PMID: 5172225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
148
|
Chiodini PG, Liuzzi A, Botalla L. [Behavior of blood somatotropin in Turner's syndrome]. FOLIA ENDOCRINOLOGICA 1971; 24:377-82. [PMID: 5172226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
149
|
Keaney J, Liuzzi A, Freedman GS. Large dose errors due to redistribution of 133-Xe in carpules and plastic syringes. J Nucl Med 1971; 12:249-50. [PMID: 4931799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
150
|
Liuzzi A, Chiodini PG, Cremoncini C, Botalla L, Spinelli F. [Behavior of somatotropinemia and insulinemia in some forms of short stature]. FOLIA ENDOCRINOLOGICA 1969; 22:373-91. [PMID: 5409261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|